Current status and future prospects of drug eluting stents for restenosis / Sadašnjost i budućnost stentova za restenozu koji otpuštaju lijekove
Open Access
|Jan 2013References
- 1. E. Sousa, P. Serruys and M. Costa, New frontiers in cardiology: drug-eluting stents: Part I,(2003) 2274-2279; DOI: 10.1161/01.CIR.0000069330.41022.90.
- 2. E. Edelman and C. Rogers, Pathobiologic responses to stenting,.(1998) 4E-6E; DOI: 10.1016/S0002-9149(98)00189-1.
- 3. P. Serruys, B. Strauss and H. Van Beusekom, Stenting of coronary arteries: has a modern Pandora’s Box been opened?.(1991) 143B-154B; DOI: 10.1016/0735-1097(91)90951-5.
- 4. M. Costa, D. Foley and P. Serruys,, in(Eds. E. Grech and D. Ramsdale), 2nd ed., Martin Dumitz, London 2002, pp. 279-294.
- 5. D. Whelan, H. Van Beusekom and W. Van der Giessen, Mechanisms of drug loading and release kinetics,(1998) 127-131.
- 6. W. Van der Giessen, A. Lincoff and R. Schwartz, Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries,(1996) 1690-1697; DOI: 10.1161/01.CIR.94.7.1690.
- 7. D. Drachman, E. Edelman and P. Seifert, Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months,.(2000) 2325-2332; DOI: 10.1016/S0735-1097(00)01020-2.
- 8. B. Ratner, The blood compatibility catastrophe,(1993) 283-287; DOI: 10.5897/AJPP11.107.
- 9. M. Lovich, C. Creel and K. Hong, Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel,.(2001) 1324-1335; DOI: 10.1002/JPS.1085.
- 10. R. Braun-Dullaeus, M. Mann and V. Dzau, Cell cycle progression: new therapeutic target for vascular proliferative disease,(1998) 82-89; DOI: 10.1161/01.CIR.98.1.82.
- 11. C. Morton Allison, D. Crossman and J. Gunn, The influence of physical stent parameters upon restenosis,.(2004) 196-205; DOI: 10.1016/J.PATBIO.2004.03.013.
- 12. C. Rogers, Optimal stent design for drug delivery,(2004) S9-S15.
- 13. K. Lau, A. Johan, U. Sigwart and J. Hung, A stent is not just a stent: stent construction and design do matter in its clinical performance,(2004) 305-312.
- 14. A. Colombo, G. Stankovic and J. W. Moses, Selection of coronary stents,.(2002) 1021-1033.
- 15. D. Stoeckel, C. Bonsignore and S. Duda, A survey of stent designs,(2002) 137-147.
- 16. L. Lim, Biocompatability of stent materials,(2004) 33-37.
- 17. J. Bier, P. Zalesky and S. Li, A new bioabsorbable intravascular stent: in vitro assessment of hemodynamic and morphometric characteristics,.(1992) 187-194.
- 18. B. Berk, J. Gordon and R. Alexander, Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty,.(1991) 111B-117B; DOI: 10.1016/0735-1097(91)90946-7.
- 19. C. Pepine, J. Hirshfeld and R. Macdonald, A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty,(1990) 1753-1761; DOI: 10.1161/01.CIR.81.6.1753.
- 20. I. De Scheerder, K. Wang and K. Wilczek, Local methylprednisolone inhibition of foreign body response to coated intracoronary stents,(1996) 161-166.
- 21. A. M. Lincoff, J. G. Furst and S. G. Ellis, Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model,(1997) 808-816; DOI: 10.1016/S0735-1097(96)00584-0.
- 22. D. Holmes, M. Savage and J. LaBlanche, Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial,(2002) 1243-1250. DOI: 10.1161/01.CIR.0000028335.31300DA.
- 23. A. Farb, M. John, E. Acampado, F. D. Kolodgie, M. F. Prescott and R. Virmani, Oral everolimus inhibits in-stent neointimal growth,(2002) 2379-2384; DOI: 10.1161/01.CIR.0000033973.06059.04.
- 24. P. B. Schiff and S. B. Horwitz, Taxol stabilizes microtubules in mouse fibroblast cells,(1980) 1561-1565.
- 25. P. W. Serruys, Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis,(1995) 2759-2760.
- 26. R. K. Aggarwal, D. C. Ireland, M. A. Azrin, M. D. Ezekowitz, D. P. de Bono and A. H. Gershlick, Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody,(1996) 3311-3317; DOI: 10.1161/01.CIR.94.12.3311.
- 27. C. Li, W. J. Cantor, N. Nili, R. Robinson, L. Fenkell and Y. L. Tran, Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor,(2002) 1852-1858; DOI: 10.1016/S0735-1097(02)01873-9.
- 28. C. Rogers, S. Parikh, P. Seifert and E. R. Edelman, Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair,(1996) 2909-2914; DOI: 10.1161/01.CIR.94.11.2909.
- 29. J. Aoki, P. W. Serruys, H. van Beusekom, A. T. Ong, E. P. McFadden and G. Sianos, Endothelial progenitor cell capture by stents coated with antibody against CD34: The healing-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry,(2005) 1574-1579.
- 30. D. J. Cohen, Economics of coronary restenosis: implications of drug-eluting stents, http://www.tctmd.com/show.aspx?id=58808; last access: April 22, 2012
- 31. P. W. Serruys, P. de Jaegere, F. Kiemeneij, C. Macaya, W. Rutsch, G. Heyndrickx, H. Emanuelsson, J. Marco, V. Legrand, P. Materne, J. Belardi, U. Sigwart, A. Colombo, J. J. Gay, P. Henvel, J. Delcan and M. Morel, A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease,(1994) 489-495; DOI: 10.10.1056/NEJM199408253310801.
- 32. H. Tamai, K. Igaki, E. Kyo, K. Kosuga, A. Kawashima, S. Matsui, H. Komori, T. Tsuji, S. Motohara and H. Uehata, Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans,(2000) 399-404; DOI: 10.1161/01.CIR.102.4.399.
- 33. J. A. Ormiston, P. W. Serruys, E. Regar, D. Dudek, L. Thuesen, M. W. Webster, Y. Onuma, H. M. Garcia-Garcia, R. McGreevy and S. Veldhof, A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial,(2008) 899-907; DOI: 10.1016/S0140-6736(08)60415-8.
- 34. J. A. Ormiston and P. W. Serruys, Bioabsorbable coronary stents,(2009) 255-260; DOI: 10.1161/CIRCINTERVENTIONS.109.859173.
- 35. S. Ramcharitar and P. W. Serruys, Fully biodegradable coronary stents: progress to date,(2008) 305-314.
- 36. R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. de Bruyne, F. R. Eberli, P. Erne, M. Haude, B. Heublein, M. Horrigan, C. Ilsley, D. Bose, J. Koolen, T. F. Luscher, N. Weissman and R. Waksman, Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial,(2007) 1869-1875; DOI: 10.1016/S0140-6736(07)60853-8.
- 37. N. Tada, R. Virmani, G. Grant, L. Bartlett, A. Black, C. Clavijo, U. Christians, R. Betts, D. Savage, S. H. Su, J. Shulze and S. Kar, Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model,(2010) 174-183; DOI: 10.1161/CIRCINTERVENTIONS.109.87522.
- 38. J. R. Costa, Jr., A. Abizaid, R. Costa, F. Feres, L. F. Tanajura, G. Maldonado, R. Staico, D. Siqueira, A. G. Sousa, R. Bonan and J. E. Sousa, 1-Year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial,(2009) 422-427; DOI: 10.1016/j.jcin.2009.02.009.
- 39. J. Aoki, P. W. Serruys, H. van Beusekom, A. T. L. Ong, E. P. McFadden and G. Sianos, Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry,(2005) 1574-1579; DOI: 10.1016/j.jacc.2005.01.048.
- 40. H. J. Duckers, S. Silber, R. D. Winter, P. D. Heijer, B. Rensing and M. Rau, Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent,(2007) 67-75.
- 41. M. Co, E. Tay, C. H. Lee, K. K Poh, A. Low and J. Lim, Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow-up,(2008) 128-132; DOI: 10.1016/j.ahj.2007.08.031.
- 42. A. Abizaid and J. R. Costa, Jr., New drug-eluting stents: An overview on biodegradable and polymer-free next-generation stent system,(2010) 384-393; DOI: 10.1161/CIRCINTERVENTIONS.109.891192.
- 43. C. Lovadahl, J. Thyber and A. Hultgardh-Nilsson, The synthetic metalloproteinase inhibitor batimastat suppresses injury induced phosphorylation of MAP kinase ERK/ERK2 and phenotypic modification of arterial smooth muscle cells in vitro,(2000) 345-354; DOI: 10.1159/000025750.
- 44. P. W. Serruys, S. Garg, A. Abizaid, J. Ormiston, S. Windecker, S. Verheye, C. Dubois, J. Stewart, K. E. Hauptmann, J. Schofer, K. Stangl, B. Witzenbichler, M. Wiemer, E. Barbato, T. de Vries, A. M. den Drijver, H. Otake, L. Meredith, S. Toyloy and P. Fitzgerald, A randomised comparison of novolimus-eluting and zotarolimus eluting coronary stents: 9-month follow-up results of the EXCELLA II study,(2010) 195-205.
Language: English, Croatian, Slovenian
Page range: 473 - 496
Published on: Jan 15, 2013
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2013 Maulik J. Patel, Sanjay S. Patel, Nidhi S. Patel, Natvarlal M. Patel, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.